MaxQ AI, the industry-leading healthcare technology company that delivers comprehensive clinical workflow solutions assisting with improved patient triage and diagnosis, announced multiple advancements, including enhanced functionality, new security certifications, and an expanded premier partner within the PACS healthcare sector.
In continued partnership with Intel, MaxQ AI has recently launched the second version of the Accipio Clinical Platform, utilized in reading adult non-contrast head CT exams. V2 features enhanced functionality to support seamless and secure integrations throughout MaxQ’s CT, PACS, radiology reporting, and curated AI partner base of global acute hospitals. The platform is comprised of Accipio Ix (Intracranial Hemorrhage (ICH) triage and notification, Accipio Ax (Slice-Level Annotation), and Accipio Dxg (Triage for ICH Presence or Absence)**.
It has been well established that timely intervention is critical to patient outcomes. The adage “time is brain” is well-coined as 1.9 million neurons are lost per minute during an untreated ischemic stroke*. The global ICH burden in 2010 was reported to include 5.3 million cases and over 3 million deaths, with half of the fatalities occurring within 48 hours of symptom onset*.
“Each month Accipio Ix processes nearly one-thousand head CT scans, including upwards of 30 stroke cases per week, at Capital Health,” said Dr. Ajay Choudhri, Chairman of the Department of Radiology at Capital Health Hospitals in New Jersey. “With Accipio Ax, we will be able to benefit from a comprehensive solution for triage through the intelligent workflow prioritization of MaxQ Xpress and slice-level preview of ICH, including the exclusive Accipio Ax SliceMap, which will guide users rapidly to CT images with suspected ICH.”
Fast Answers With AI On Intel: To handle the demands of the acute care environment, MaxQ AI chose Intel AI technologies for cost-effective performance in a flexible and easily managed platform. The company’s machine-learning experts optimized the solution’s performance by working with the Intel® AI Builders program, which brings together a range of companies and organizations committed to fulfilling the potential of AI. The collaboration paid off. MaxQ AI’s optimizations produced a 3x improvement in the image processing time for Accipio Ix without compromising accuracy, according to Steve Kohlmyer, vice president of research and clinical collaborations at MaxQ AI. “The original product release of Accipio Ix took an average of 4.1 minutes to process a radiology exam,” he said. “The average processing time for the first 4,000 exams at Capital Health has been 1.4 minutes. That improvement reflects the optimization we did through the Intel AI Builders partnership.” MaxQ AI has taken advantage of a broad range of Intel® tools and technologies. It uses the Intel® Math Kernel Library for Distributed Neural Networks (Intel® MKL-DNN) to fine-tune model performance on Intel processors. MaxQ AI also deploys the Intel Distribution of OpenVINO toolkit to speed up image recognition applications on Intel® architecture-based platforms.¹
In addition to releasing the second generation of Accipio, MaxQ AI has also partnered with Fujifilm Medical Systems U.S.A., Inc. The company entered a multi-year global distribution agreement to deliver MaxQ’s suite through the Fujifilm Synapse PACS platform. As the leading provider of enterprise imaging solutions, Fujifilm will help commercialize the clinical AI applications.
Moreover, to further demonstrate its commitment to the highest standards of data protection, MaxQ has achieved ISO 27799 certification and ISO 27001 recertification. Both certifications are widely recognized international standards for information security management systems. These qualifications separate MaxQ as a comprehensive and secure solution for the healthcare industry. Cybersecurity causes a threat to not only revenue and expenses, but also patient care and healthcare organizations’ reputations. This is why MaxQ sought to become the only AI platform company offering their integrated solutions through ISO 27001 & ISO 27799 cybersecurity standards.
Currently, Accipio devices are globally available with multiple regulatory approvals. They are seamlessly deployed through MaxQ’s trusted channel partner base, and used by Neuroradiology teams to make treatment path decisions while lessening burden and burnout. The software enables providers to make faster, more accurate decisions when diagnosing intracranial hemorrhage, stroke, brain trauma, and other serious conditions.
This unique AI experience is transforming healthcare by empowering physicians to provide “smarter care” in moments where minutes matter. To learn more, visit www.maxq.ai or follow the company on LinkedIn.
*References Available Upon Request
**MaxQ Device Regulatory Status Available at www.maxq.ai
1 Baseline: Testing conducted JAN 2019, 1 socket Intel® Core™ i9-7960X, 16 cores per socket, OS Microsoft Windows Server* 2016 Standard, Kernel 10.0.14393 Build 14393, Total memory 64.0 GB, SMBIOS Version 3.0, Optimized: Testing conducted JAN 2019, 1 socket Intel® Core™ i9-7960X, 16 cores per socket, OS Microsoft Windows Server 2016 Standard, Kernel 10.0.14393 Build 14393, Total memory 64.0 GB, SMBIOS Version 3.0, Python 3.4, Caffe2 0.8.0 (stock), VTune 2019 Update1, OpenVINO SDK v3.34.
Blog List / How MaxQ AI Is Changing The Healthcare Industry - In Continued Partnership With Intel